Comparative Pharmacology
Head-to-head clinical analysis: LEVORA 0 15 30 21 versus MIBELAS 24 FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVORA 0 15 30 21 versus MIBELAS 24 FE.
LEVORA 0.15/30-21 vs MIBELAS 24 FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; levonorgestrel inhibits ovulation and thickens cervical mucus, impairing sperm penetration. Also induces endometrial atrophy.
Combination hormonal contraceptive: ethinyl estradiol suppresses LH and FSH, primarily inhibiting ovulation; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity, increasing cervical mucus viscosity and altering endometrial morphology.
One tablet orally once daily for 21 days, followed by 7 tablet-free days.
One tablet orally once daily for 24 days followed by 4 placebo tablets. Each tablet contains 75 mcg desogestrel and 0.02 mg ethinyl estradiol.
None Documented
None Documented
20-30 hours for ethinyl estradiol; 2-4 hours for levonorgestrel. Steady-state reached in 5-7 days
Drospirenone: ~30 hours; Ethinyl estradiol: ~17 hours. Steady-state reached after ~10 days for drospirenone.
Urine (50-60% as metabolites), feces (30-40% as glucuronides); <10% unchanged
Drospirenone: 40-50% renal as metabolites, <10% unchanged; ~50% fecal. Ethinyl estradiol: ~40% renal, 60% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive